These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26571097)

  • 1. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M; Vila C
    Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 15. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó
    Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
    Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.